Skip to main content

Table 1 DawnRank analysis of entinostat-treated MMTV/Neu samples

From: Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer

Untreated (N = 6) Entinostat-3wks (N = 4) Entinostat-6wks (N = 4) Entinostat-resistant (N = 8)
Gene Percent rank Chr Gene Percent rank Chr Gene Percent rank Chr Gene Percent rank Chr
MAX 1 12 JUN 0.977 4 JUN 0.997 4 JUN 0.999 4
CALM1 0.995 12 CDC42 0.975 4 CDC42 0.994 4 JAK1 0.995 4
HIF1A 0.990 12 JAK1 0.969 4 JAK1 0.992 4 CDC42 0.990 4
ACTN1 0.986 12 LCK 0.969 4 LCK 0.989 4 CDKN2A 0.989 4
FOS 0.981 12 LYN 0.965 4 LYN 0.987 4 LCK 0.987 4
HSP90AA1 0.976 12 MAP3K7 0.960 4 MAP3K7 0.984 4 TGFBR1 0.984 4
FOXA1 0.972 12 ERBB2 0.959 11 CDKN2A 0.982 4 LRP8 0.983 4
ARF6 0.967 12 CDKN2A 0.952 4 ZBTB17 0.979 4 ZBTB17 0.981 4
FBLN5 0.963 12 TGFBR1 0.950 4 TGFBR1 0.977 4 TLE1 0.980 4
NCOA1 0.958 12 RBBP4 0.948 4 RBBP4 0.974 4 LYN 0.980 4
NFKBIA 0.953 12 ZBTB17 0.944 4 LRP8 0.972 4 RBBP4 0.979 4
  1. Chr, mouse chromosome; Entinostat-3wks, Entinostat-6wks, Entinostat-resistant are samples treated with entinostat for 3 weeks, 6 weeks, and until progression, respectively